Home / Specialty Pharmacy (page 20)

Specialty Pharmacy

CVS Health Finalizes Target Pharmacy Deal

WOONSOCKET, R.I. and MINNEAPOLIS, Dec. 16, 2015 /PRNewswire/ — CVS Health Corporation (NYSE: CVS) and Target Corporation (NYSE: TGT) announced today that CVS Health has completed the acquisition of Target’s pharmacy and clinic businesses for approximately $1.9 billion. With the completion of the transaction, CVS Health acquired Target’s 1,672 pharmacies across …

Read More »

FDA Lifts IND Clinical Hold for Three of Advaxis’ Product Candidates

PRINCETON, N.J., Dec. 16, 2015 (GLOBE NEWSWIRE) — Advaxis, Inc. (NASDAQ:ADXS), a clinical-stage biotechnology company developing cancer immunotherapies, today announced that the U.S. Food and Drug Administration (FDA) has lifted the clinical hold on all of the company’s Investigational New Drug (IND) applications for its three product candidates: axalimogene filolisbac …

Read More »

Survey Shows Supply Chain Effectiveness Considered Among Top Priorities to Hospital Decision Makers

DUBLIN, Ohio, Dec. 14, 2015 /PRNewswire/ — Reimbursement is the biggest problem facing health systems today, followed closely by the increasingly high cost of supplies, according to a new, national survey of hospital executives commissioned by Cardinal Health. Financial issues, drug shortages and efficiency of the organization follow as the …

Read More »

Cardiorentis’ ADHF Drug Receives Fast Track Status from the FDA

ZUG, Switzerland, Dec. 11, 2015 /PRNewswire/ — Cardiorentis AG, a privately held biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track status to Ularitide, an investigational therapy for the treatment of acute decompensated heart failure (ADHF). The FDA’s Fast Track process is intended …

Read More »

Center for Healthcare Supply Chain Research Releases Specialty Pharmaceutical Distribution: Facts, Figures and Trends

ARLINGTON, Va., December 3, 2015 — HDMA’s Center for Healthcare Supply Chain Research has published the latest edition of its annual benchmarking publication, Specialty Pharmaceutical Distribution: Facts, Figures and Trends (2015 Edition). The seventh edition is sponsored by CuraScript Specialty Distribution; Genentech, A Member of the Roche Group; and Pharmacy …

Read More »

Amgen and Merck Enter Cancer Immunotherapy Collaboration for NHL

THOUSAND OAKS, Calif. and KENILWORTH, N.J., Dec. 4, 2015 /PRNewswire/ — Amgen (NASDAQ: AMGN) and Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced a cancer immunotherapy collaboration to support a Phase 1b/3 study investigating BLINCYTO® (blinatumomab) in combination with KEYTRUDA® (pembrolizumab) in patients with diffuse large …

Read More »

Zafgen Reports a Second Patient Died in Beloranib Study

BOSTON, Dec. 02, 2015 (GLOBE NEWSWIRE) — Zafgen, Inc. (Nasdaq:ZFGN), a biopharmaceutical company dedicated to significantly improving the health and well-being of patients affected by obesity and complex metabolic disorders, today provided an update on the open label extension (OLE) portion of the pivotal Phase 3 ZAF-311 bestPWS clinical trial …

Read More »

FDA Approves Lilly’s Portrazza for Patients with Squamous NSCLC

INDIANAPOLIS, Nov. 24, 2015 /PRNewswire/ —  Eli Lilly and Company (NYSE: LLY) announced today that the U.S. Food and Drug Administration (FDA) has approved Portrazza™ (necitumumab injection for intravenous use, 800 mg/50 mL), in combination with gemcitabine and cisplatin, as the first biologic for the first-line treatment of people with …

Read More »

Roche’s Melanoma Drug Performs Well in Early-Stage Study

Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced data from the pivotal coBRIM study, which showed that Cotellic (cobimetinib) in combination with Zelboraf (vemurafenib) helped people with BRAF V600E and V600K mutation-positive unresectable or metastatic melanoma live significantly longer (overall survival; OS) than with Zelboraf alone.1 Cotellic plus Zelboraf reduced …

Read More »